<DOC>
	<DOCNO>NCT02280044</DOCNO>
	<brief_summary>This study randomize , double-blinded , placebo-controlled , in-patient trial evaluate prophylactic efficacy rifaximin campylobacteriosis follow challenge C. jejuni .</brief_summary>
	<brief_title>Efficacy Rifaximin Preventing Campylobacteriosis</brief_title>
	<detailed_description>28 healthy volunteer give inform consent enrol participate study determine efficacy prophylactic rifaximin prevent diarrheal illness follow challenge C. jejuni , strain CG8421 . Volunteers screen inclusion exclusion criterion admit inpatient unit Center Immunization Research Johns Hopkins University . Volunteers treat rifaximin placebo double blind manner four day , begin day prior challenge . On day challenge , volunteer give 5x10 ( 5 ) C. jejuni bicarbonate buffer monitor treat symptom . Stools culture daily excretion C. jejuni subject treat antibiotic insure challenge strain clear prior discharge . Subjects follow six month follow inpatient phase detect adverse event follow study .</detailed_description>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Dysentery</mesh_term>
	<mesh_term>Campylobacter Infections</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>1 . Male female 18 50 year age , inclusive 2 . General good health , without significant medical illness , abnormal physical examination finding clinically significant laboratory abnormality , determine PI ( may consult Research Monitor casebycase basis ) 3 . Demonstrate comprehension protocol procedure knowledge Campylobacter illness pass write examination ( pas grade â‰¥ 70 % ) 4 . Willing participate inform consent obtain 5 . Available planned followup visit remain available clinic visit ( examination , blood draw stool collection ) monitoring 90 day postchallenge phone 180 day postchallenge 6 . If subject female , eligible enter : Nonchildbearing potential ( i.e. , physiologically incapable become pregnant , include female postmenopausal . For purpose study , postmenopausal define one year without menses ) ; must documentation undergone tubal ligation hysterectomy . OR Childbearing potential ; negative serum pregnancy test screen negative urine pregnancy test admission ( Study Day 1 ) , agree use efficacious hormonal barrier method birth control study , abstinence acceptable General health/issues 1 . Presence significant medical condition ( e.g. , psychiatric condition ; gastrointestinal disease , peptic ulcer , symptom evidence active gastritis/dyspepsia , inflammatory bowel disease , irritable bowel syndrome ( define Rome III criterion medical diagnosis ) ; alcohol illicit drug abuse/dependency ) laboratory abnormality opinion investigator preclude participation study 2 . Evidence Immunoglobulin A deficiency ( serum IgA &lt; 7 mg/dL limit detection assay ) 3 . Positive serology result HIV , HBsAg , Hepatitis C virus antibody 4 . Positive urine toxicology screen 5 . Significant abnormality screen laboratory hematology serum chemistry , determine PI PI consultation Research Monitor sponsor 6 . Use medication know affect immune function ( e.g. , corticosteroid others ) within 30 day precede receipt challenge inoculum plan use active study period 7 . Nursing mother day admittance inpatient unit Studyspecific exclusionary condition base potential increase risk complicate outcome ascertainment . ( See protocol detail complete list exclusion . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Campylobacter jejuni</keyword>
	<keyword>rifaximin</keyword>
	<keyword>antibiotic prophylaxis</keyword>
	<keyword>dysentery</keyword>
	<keyword>diarrhea</keyword>
</DOC>